PSD4

Across TCGA pan-cancer cohorts, PSD4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PSD4 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PSD4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PSD4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where PSD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.922	0.364	.002	21	view →
LUAD	OS	Tertile	III,IV	0.172	0.787	.001	17	view →
CCRCC	DFS	Tertile	All	0.869	1.000	.004	16	view →
GBM	DFS	Quartile	All	0.644	0.249	.006	4	view →
HNSC	OS	Median	III,IV	1.000	0.946	.037	3	view →
LSCC	DFS	Quartile	All	0.815	0.369	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PSD4–PDAC (DFS)

Open the PDAC breakdown →